Biogen registers first-in-human trial for STMN2-targeted ASO in broad ALS (AllSci Corp) - Oct 21, 2026 - "Biogen has registered a first-in-human Phase I/II trial of BIIB147, an investigational antisense oligonucleotide (ASO) that the company said targets stathmin-2 (STMN2) pre-mRNA in adults with ALS who carry no pathogenic or uncertain variants in the SOD1 or FUS genes. According to a Biogen Q2 2026 SEC filing, the company exercised an option in Q2 2026 to obtain a worldwide exclusive, royalty-bearing licence from Ionis Pharmaceuticals to develop and commercialize BIIB147...The study — registered as NCT07855211 — is a randomized, quadruple-masked, placebo-controlled multiple-ascending-dose study with an open-label extension, enrolling 69 adults at two US sites. Four cohorts receive intrathecal BIIB147 or placebo for 12–20 weeks before transitioning to an open-label maintenance phase lasting up to 340 weeks, with primary completion estimated for January 2034."
First-in-human • Trial completion date • Trial status • Amyotrophic Lateral Sclerosis
|